Mealey's (March 29, 2019, 6:05 PM EDT) -- TULSA, Okla. — The Oklahoma federal judge presiding over the Herceptin multidistrict litigation on March 20 granted summary judgment to defendant Genentech Inc. after finding that the complaints by cancer treatment providers about the vial volume for the breast cancer drug are preempted by federal law (In Re: Genentech, Inc. Herceptin [Trastuzumab] Marketing and Sales Practices Litigation, MDL Docket No. 2700, No. 16-md-2700, N.D. Okla., 2019 U.S. Dist. LEXIS 45872)....